Controversies in Contraception
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Did you know that women weighing greater than 198 pounds (90 kilos) have a high risk of pregnancy on all forms of hormonal contraceptives? Can you imagine telling a patient that she is too overweight to go on the pill? Fortunately, we have an expert on the show that can help us with this delicate problem. Our guest is Doctor Robert Hatcher, a professor of Gynecology and Obstetrics at the Emory University School of Medicine. He iss the lead author of Contraceptive Technology, perhaps the most comprehensive book on contraception available. First written by Dr. Hatcher in 1967, the book’s 19th edition will be available shortly.
Overview
Did you know that women weighing greater than 198 pounds (90 kilos) have a high risk of pregnancy on all forms of hormonal contraceptives? Can you imagine telling a patient that she is too overweight to go on the pill? Fortunately, we have an expert on the show that can help us with this delicate problem. Our guest is Doctor Robert Hatcher, a professor of Gynecology and Obstetrics at the Emory University School of Medicine. He iss the lead author of Contraceptive Technology, perhaps the most comprehensive book on contraception available. First written by Dr. Hatcher in 1967, the book’s 19th edition will be available shortly.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?